Outcomes of Lobar and Sublobar Resection for Clinical Stage I Lung Neuroendocrine Tumors: An ENETS Center of Excellence Experience

<b>Objectives:</b> Lung neuroendocrine tumors (LNETs) are rare, comprising 1-2% of lung cancers. This study aimed to compare overall survival (OS) and recurrence-free survival (RFS) after lobar resection versus sublobar resection for LNETs and to identify factors associated with prognosis and resection extent. <b>Methods:</b> We retrospectively analyzed patients with clinical stage I (T ≤ 4 cm, N0M0) typical or atypical carcinoid who underwent curative resection at Hadassah Medical Center and Kaplan medical Center between 2010 and 2024. <b>Results:</b> Seventy patients (mean age 56.8 ± 16 years; 63% female) were included. Lobar resection was performed in 40 (57%) and sublobar resection in 30 (43%; 15 segmentectomies, 15 wedge resections). Pathology revealed 50 typical carcinoid (71.43%) and 20 atypical carcinoid (28.57%). Final pathological stage was I in 57 patients (81.42%), II in 9 (12.86%), and III in 4 (5.71%), reflecting surgical upstaging in 13 patients (18.57%), all due to nodal involvement. Atypical carcinoid was associated with worse RFS, nodal upstaging, and adjuvant therapy (all <i>p</i> < 0.01). Patients undergoing sublobar resection were older, had higher comorbidity scores, more frequently presented with peripheral tumors, and underwent less frequent lymph node assessment (all <i>p</i> < 0.01). At a median follow-up of 3.8 years for OS and 2.0 years for RFS, survival rates were 95.7% for both. Neither OS, RFS, nor postoperative normalization of plasma pro-gastrin-releasing peptide (ProGRPp) levels differed significantly between lobar resection and sublobar resection (<i>p</i> = 0.94, <i>p</i> = 0.42, and <i>p</i> = 0.205, respectively). <b>Conclusions:</b> Sublobar resection may represent an acceptable surgical option for selected patients with clinical stage I LNETs, particularly for peripheral tumors ≤ 2 cm in older or comorbid patients. The high rate of nodal upstaging underscores the need for lymph node assessment, irrespective of resection extent.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-11-08
DOI
https://doi.org/10.3390/jcm14227927
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes of Lobar and Sublobar Resection for Clinical Stage I Lung Neuroendocrine Tumors: An ENETS Center of Excellence Experience

Amit Korach, Karine Atlan, Simona Ben‐Haim, Uzi Izhar et al.
Journal of Clinical Medicine
Neuroendocrine Tumor Research Advances
article

Outcomes of Lobar and Sublobar Resection for Clinical Stage I Lung Neuroendocrine Tumors: An ENETS Center of Excellence Experience

Amit Korach, Karine Atlan, Simona Ben‐Haim, Uzi Izhar, Guy Pines, Islam Idais, Ofra Maimon, Gal Aviel, Oz M. Shapira, Ori Wald, Simona Grozinsky‐Glasberg, Anat Bel-Ange, Benjamin Nisman, Ranin Hojerat
article en

Abstract

<b>Objectives:</b> Lung neuroendocrine tumors (LNETs) are rare, comprising 1-2% of lung cancers. This study aimed to compare overall survival (OS) and recurrence-free survival (RFS) after lobar resection versus sublobar resection for LNETs and to identify factors associated with prognosis and resection extent. <b>Methods:</b> We retrospectively analyzed patients with clinical stage I (T ≤ 4 cm, N0M0) typical or atypical carcinoid who underwent curative resection at Hadassah Medical Center and Kaplan medical Center between 2010 and 2024. <b>Results:</b> Seventy patients (mean age 56.8 ± 16 years; 63% female) were included. Lobar resection was performed in 40 (57%) and sublobar resection in 30 (43%; 15 segmentectomies, 15 wedge resections). Pathology revealed 50 typical carcinoid (71.43%) and 20 atypical carcinoid (28.57%). Final pathological stage was I in 57 patients (81.42%), II in 9 (12.86%), and III in 4 (5.71%), reflecting surgical upstaging in 13 patients (18.57%), all due to nodal involvement. Atypical carcinoid was associated with worse RFS, nodal upstaging, and adjuvant therapy (all <i>p</i> < 0.01). Patients undergoing sublobar resection were older, had higher comorbidity scores, more frequently presented with peripheral tumors, and underwent less frequent lymph node assessment (all <i>p</i> < 0.01). At a median follow-up of 3.8 years for OS and 2.0 years for RFS, survival rates were 95.7% for both. Neither OS, RFS, nor postoperative normalization of plasma pro-gastrin-releasing peptide (ProGRPp) levels differed significantly between lobar resection and sublobar resection (<i>p</i> = 0.94, <i>p</i> = 0.42, and <i>p</i> = 0.205, respectively). <b>Conclusions:</b> Sublobar resection may represent an acceptable surgical option for selected patients with clinical stage I LNETs, particularly for peripheral tumors ≤ 2 cm in older or comorbid patients. The high rate of nodal upstaging underscores the need for lymph node assessment, irrespective of resection extent.

Journal of Clinical MedicineVol. 14(22)
University College London Hospitals NHS Foundation Trust (GB), Hebrew University of Jerusalem (IL), Hadassah Medical Center (IL), Kaplan Medical Center (IL), University College London (GB)
Hebrew University of Jerusalem
Openalex Percentile: Top 56%
Neuroendocrine Tumor Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.